Xeris Pharmaceuticals | XERS - Ebitda



金融业
股票价格
USD
资产
USD 411.91M
现金及等价物
USD 121.75M
销售成本
USD 10.57M
流动资产
USD 274.76M
流动负债
USD 189.57M
债务
USD 258.55M
EBIT
USD 9.12M
EBITDA
USD 12.33M
员工
377
EPS每股收益
USD 0.01
股本和储备
USD -9.73M
销售毛利
USD 72.55M
债务利息支出
USD 6.88M
利息收入
USD 1.2M
贷款资金
USD 188.81M
市值
USD 1.24B
净收入
USD 2.23M
营业费用
USD 75.21M
营业利润
USD 7.92M
普通股股本
USD 172.56M
PE价格收益
76.05
税前利润
USD 2.23M
销售收入
USD 83.13M
销售和管理费用
USD 53.14M
股票
USD 80.93M
贸易债权人
USD 9.34M
应收帐款人
USD 56.3M


Ebitda 更改 日
Celltrion KRW 19.64B 1.85B 2026-03
Cspc Pharmaceutical CNY 2.19B 21.88M 2024-12
Deva Holding AS TRY 882.9M 201.7M 2023-09
Dianthus Therapeutics USD -46.46M 6.27M 2026-03
Divis Laboratories Ltd INR 12.62B 3.28B 2026-06
Eli Lilly USD 10.29B 1.86B 2026-03
Kangmei Pharma CNY -12.72M 30.02M 2026-03
Knight Therapeutics CAD 24.45M 3.46M 2025-12
Laboratorios Farma EUR 34.94M 102.95M 2025-06
Malin Corporation EUR -1.1M 200K 2024-12
Medical Developments International AUD 1.78M 3.78M 2024-12
Nektar Therapeutics USD -38.9M 7.09M 2026-03
Neuren Pharmaceuticals AUD 11.14M 165.56M 2025-12
Organigram Holdings CAD -4.76M 10.02M 2026-03
Pacira USD 48.67M 8.43M 2026-06
Perrigo USD 141.6M 1.34B 2026-03
Pharma Mar EUR 700K 2.01M 2026-06
Qiagen NV USD 207.66M 59.56M 2026-06
Sartorius EUR 280.5M 13.2M 2026-06
Sino Biopharmaceutical CNY 2.59B 1.57B 2024-12
Supernus Pharmaceuticals USD 31.6M 2.37M 2026-06
Tilray USD 8.36M 1.82M 2025-09
Zealand Pharma A/S -379M 348.47M 2026-03
Zhangzhou Pientzehuang Pharmaceutical CNY 882.7M 351.1M 2026-03